Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1
by Zacks Equity Research
Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.
Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate
Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat
by Zacks Equity Research
Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.
AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2017 loss of 12 cents per share, narrower than the Zacks Consensus Estimate as well as year-ago loss of 13 cents.
Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.
Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus
by Zacks Equity Research
Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.
Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store?
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) is expected to report first-quarter 2017 results on May 4. Celldex's performance has been encouraging with a three-quarter average positive surprise of 8.06%.
Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD
by Zacks Equity Research
The Q1 earnings season is in full swing with financial results from 288 S&P 500 members or 63.8% of the index already out as of Apr 28, 2017.
Company News for April 28, 2017
by Zacks Equity Research
Companies in the News are: F,LUV,UNP,BMY
Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More
by Arpita Dutt
Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.
Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View
by Zacks Equity Research
Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.
Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY
by Zacks Equity Research
Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.
Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.
Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.
Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?
by Sweta Killa
Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.
3 Key Factors to Look Out for in Biogen's Q1 Results
by Arpita Dutt
With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.
Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL
by Arpita Dutt
Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.
Is J&J's Pharma Sales Slowdown a Warning for Other Players?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.
Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).
Bristol-Myers and Nordic Ink Biomarker Collaboration Deal
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.
5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates
by Zacks Equity Research
2017 is expected to be a strong year for drug stocks.
Biogen to License Alzheimer Candidate from Bristol-Myers
by Zacks Equity Research
Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.
J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?
by Zacks Equity Research
We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.
Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops
by Arpita Dutt
Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.
Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.